MedTrace Logo

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

NCT03470103 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 643

Last updated 2021-06-25

No results posted yet for this study

Summary

The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin America for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc.) and are being switched to intravitreal aflibercept injection.

Conditions

  • Macular Degeneration

Interventions

DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Use of intravitreal aflibercept in routine clinical practice in Latin America

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-28
Primary Completion
2020-09-21
Completion
2021-01-15

Countries

  • Argentina
  • Colombia
  • Costa Rica
  • Mexico

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03470103 on ClinicalTrials.gov